Predix Pharmaceuticals Announces Findings From Preclinical Cognition Studies At The 10th International Conference On Alzheimer's Disease

LEXINGTON, Mass.--(BUSINESS WIRE)--July 18, 2006--Predix Pharmaceuticals, which recently announced a definitive agreement to merge with EPIX Pharmaceuticals (NASDAQ: EPIX - News), announced today that preclinical data from studies in Alzheimer's disease with PRX-03140, a highly selective, proprietary serotonin 4 (5-HT4) receptor agonist, will be featured in an oral presentation at the 10th International Conference on Alzheimer's Disease in Madrid, Spain from July 15-20, 2006. The Conference, part of the Alzheimer's Association research program, brings together more than 5,000 researchers to share information and resources on the etiology, pathology and treatment of Alzheimer's disease and related disorders.